Design, Synthesis, and Biological Evaluation of MEK PROTACs.
Stefan VollmerDanen CunoosamyHuafei LvHuanxi FengXia LiZiyang NanWenzhen YangMatthew W D PerryPublished in: Journal of medicinal chemistry (2019)
PROteolysis TArgeting Chimeras (PROTACs) targeting the degradation of MEK have been designed based on allosteric MEK inhibitors. Inhibition of the phosphorylation of ERK1/2 was less effective with the PROTACs than a small-molecule inhibitor; the best PROTACs, however, were more effective in inhibiting proliferation of A375 cells than an inhibitor.